New drug combo shows promise for Tough-to-Treat uterine cancer
NCT ID NCT05824481
First seen Mar 14, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or returned and is no longer responding to standard chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. Participants take both drugs by mouth and through an IV, and researchers monitor side effects and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Cetntre
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.